Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed COO
Kaleido Biosciences, Inc. (KLDO) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/01/2021 8-K Quarterly results
Docs: "Kaleido Biosciences Reports Third Quarter 2021 Financial Results --Achieved primary objective of safety and tolerability in clinical study evaluating KB295 in mild-to-moderate ulcerative colitis; meaningful reduction observed in key biomarkers correlated with disease activity and inflammation-- --Remain on track to initiate Phase 2 clinical trials of KB109 in COPD and KB295 in UC in first half 2022--"
05/04/2021 8-K Quarterly results
Docs: "Third Amendment to Loan and Security Agreement, by and among Kaleido Biosciences, Inc. and each of its Qualified Subsidiaries (including Cadena Bio, Inc.), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement and Hercules Capital, Inc. †",
"Kaleido Biosciences Reports First Quarter 2021 Financial Results --Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109’s potential to reduce healthcare utilization and recovery time; initiating IND application to support further development--"
03/03/2021 8-K Quarterly results
11/02/2020 8-K Quarterly results
Docs: "Kaleido Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update - Topline Data for KB109 for the Treatment of Mild-to-Moderate COVID-19 Expected in the First Quarter of 2021 -"
08/04/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
Docs: "Kaleido Biosciences Provides Corporate Update and Reports First Quarter 2020 Financial Results - Initiating Clinical Studies of KB109 in Outpatients with Mild-to-Moderate COVID-19; Data Anticipated in Q4 2020 -",
"Corporate presentation of the Company, furnished herewith",
"Kaleido Biosciences Initiates Controlled Clinical Study of Microbiome Metabolic Therapy KB109 in Outpatients with Mild-to-Moderate COVID-19 - Top-Line Data from Study of Approximately 350 Patients Expected in Q4 2020 -"
03/02/2020 8-K Quarterly results
Docs: "Kaleido Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update"
10/30/2019 8-K Quarterly results
08/01/2019 8-K Quarterly results
Docs: "Kaleido Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update LEXINGTON, Mass., August 1, 2019 - Kaleido Biosciences, Inc. , a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced financial results for the second quarter ended June 30, 2019, and provided a corporate update. “In the second quarter we made important progress with our pipeline and now have five clinical studies underway with our Microbiome Metabolic Therapy candidates,” said Alison Lawton, President and Chief Executive Officer of Kaleido. “We initiated Kaleido’s first Phase 2 clinical trial with the advancement of KB195 for urea cycle disorders under an IND. For our KB1...",
"Kaleido Biosciences, Inc. Company Overview"
05/02/2019 8-K Quarterly results
Docs: "Kaleido Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update LEXINGTON, Mass., May 2, 2019 – Kaleido Biosciences, Inc. , a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced financial results for the first quarter ended March 31, 2019, and provided a corporate update. “The first quarter of 2019 was historic for Kaleido. During the four years since our inception, we built a library of over 1,000 Microbiome Metabolic Therapy candidates, completed seven non-IND human clinical studies, and established a pipeline with five programs spanning multiple disease areas. This rapid advancement of our platform and portfolio culm..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy